Key Takeaway: The article discusses Cognition Therapeutics and its Zervimesine treatment for Dementia with Lewy Bodies and Alzheimer Disease. However, it primarily focuses on a disclaimer regarding third-party websites, indicating that Cognition does not control or endorse external content. There are no specific details about the treatment or its efficacy.
Price reaction · baseline $0.7151 (2025-07-28 close) · hit pre-market · 2 other CGTX headline(s) in the window, move may be shared
day 0 close
-6.3%
day 1 · peak
-13%
day 3
-6.7%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
8.3%
average across 6 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Oxytocin
Phase 2 · Oxidative Stress
Full Press Release Details
You are now leaving the Cognition Therapeutics website
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.